小柯机器人

淀粉样β蛋白和tau蛋白在阿尔茨海默氏病中的协同作用
2020-08-13 17:14

近日,英国伦敦大学学院Marc Aurel Busche等研究人员总结了淀粉样β蛋白和tau蛋白在阿尔茨海默氏病中的协同作用。2020年8月10日,国际知名学术期刊《自然—神经科学》在线发表了这一论文。

研究人员表示,阿尔茨海默氏病(AD)患者在大脑中同时存在细胞外淀粉样β(Aβ)斑块和含有胞内tau的神经原纤维缠结。多年来,AD发病机理的主要观点是,Aβ的变化会加速疾病进程并引发涉及tau病理和神经变性的有害级联反应。除了此“触发”功能外,通常还认为Aβ和tau在没有特定相互作用的情况下独立发挥作用。
 
但是,现在越来越多的证据表明存在其他问题,并认为这两种病理都有协同作用。这不仅有助于解释抗Aβ临床试验的负面结果,而且还暗示可能需要重新考虑仅针对tau的试验。
 
从广泛的人类和疾病模型数据中,研究人员重点总结了与复杂的Aβ-tau相互作用有关的最新证据,并强调了其在阐明疾病发病机理和设计下一代AD治疗试验中的重要意义。
 
附:英文原文

Title: Synergy between amyloid-β and tau in Alzheimer’s disease

Author: Marc Aurel Busche, Bradley T. Hyman

Issue&Volume: 2020-08-10

Abstract: Patients with Alzheimer’s disease (AD) present with both extracellular amyloid-β (Aβ) plaques and intracellular tau-containing neurofibrillary tangles in the brain. For many years, the prevailing view of AD pathogenesis has been that changes in Aβ precipitate the disease process and initiate a deleterious cascade involving tau pathology and neurodegeneration. Beyond this ‘triggering’ function, it has been typically presumed that Aβ and tau act independently and in the absence of specific interaction. However, accumulating evidence now suggests otherwise and contends that both pathologies have synergistic effects. This could not only help explain negative results from anti-Aβ clinical trials but also suggest that trials directed solely at tau may need to be reconsidered. Here, drawing from extensive human and disease model data, we highlight the latest evidence base pertaining to the complex Aβ–tau interaction and underscore its crucial importance to elucidating disease pathogenesis and the design of next-generation AD therapeutic trials.

DOI: 10.1038/s41593-020-0687-6

Source: https://www.nature.com/articles/s41593-020-0687-6

Nature Neuroscience:《自然—神经科学》,创刊于1998年。隶属于施普林格·自然出版集团,最新IF:28.771
官方网址:https://www.nature.com/neuro/
投稿链接:https://mts-nn.nature.com/cgi-bin/main.plex


本期文章:《自然—神经科学》:Online/在线发表

分享到:

0